Objective: Much of the genetic variation in glucose levels remains to be discovered. Especially, research on gene-environment interactions is scarce. Overweight is one of the main risk factors for hyperglycemia. As transcriptional regulation is important for both weight maintenance and glucose control, we analyzed 353 single nucleotide polymorphisms (SNPs), occurring in transcriptional pathways of glucose and lipid metabolism in interaction with body mass index (BMI) on glucose levels. Research design and methods: SNPs were measured in 3244 participants of the Doetichem cohort. Non-fasting glucose levels and BMI were measured twice in 6 years. SNP Â BMI interactions were analyzed by mixed models and adjusted for age, sex, time since last meal, and follow-up time. False discovery rate (FDR) o0.2 was used to adjust for multiple testing. Results: Two SNPs in the PPARGC1A gene (rs8192678, FDR ¼ 0.07; rs3755863, FDR ¼ 0.17) showed a significant interaction with BMI. The rare allele of both SNPs was associated with significantly lower glucose levels in subjects with a BMIp25 kg m -2 (rs8192678, P ¼ 0.02; rs3755863, P ¼ 0.03). An inverse association was suggested in subjects with a BMI428 kg m -2 . A small intervention study (n ¼ 120) showed similar, though non-significant, results. Conclusions: Using a pathway-based approach, we found that BMI significantly modified the association between two SNPs in the PPARGC1A gene and glucose levels. The association between glucose and PPARGC1A was only present in lean subjects. This suggests that the effect of the PPARGC1A gene, which is involved both in fatty acid oxidation and glucose metabolism, is modified by BMI.
Introduction
Elevated plasma glucose levels are a risk factor for type 2 diabetes mellitus. Even within a non-diabetic population, there is a substantial variation in glucose levels. 1 This variation arises from both genetic and environmental factors. Identification of factors that influence glucose levels may improve our understanding of the pathogenesis of diabetes. The heritability of glucose levels, as estimated by family studies, is approximately 30%. [2] [3] [4] However, as the established polymorphisms so far explain a limited amount of genetic variation in glucose levels, 1 many more polymorphisms remain to be discovered. Most studies analyzed the individual association between polymorphisms and glucose levels without taking gene-environment interaction effects into account. Therefore, exploration of interaction effects may unravel new polymorphims. Furthermore, interaction effects may explain discrepancies between studies. Overweight is one of the main risk factors for elevated plasma glucose levels and diabetes. 5 The association between plasma glucose levels or diabetes and several polymorphisms (for example in PPARG) is modulated by obesity status. 6, 7 As transcriptional regulation is an important factor for maintaining glucose and energy homeostasis, polymorphisms occurring in transcriptional pathways related to glucose and lipid metabolism may be involved both in weight regulation and development of hyperglycemia. 8 Surveying genetic variants across these pathways in interaction with body weight could provide new insights into genetic determinants of glucose levels.
In this study, we studied the interaction of 353 single nucleotide polymorphisms (SNPs), occurring in transcriptional pathways of glucose and lipid metabolism, with body mass index (BMI) in relation to repeated measures of glucose levels in a population-based cohort study.
Materials and methods

Study population
The Doetinchem Study is a population-based cohort study on lifestyle, biological risk factors, and chronic diseases. 9 Between 1987 and 1991, 12 404 subjects, aged 20-59 years, all inhabitants of Doetinchem, a town in a rural area in east of the Netherlands, were enrolled in the baseline cohort. A random sub-sample of this cohort (63%) was invited for a second measurement round between 1993 and 1997 (response 79%) and for a third measurement in the period 1998-2002 (response 75%). Overall, the Doetinchem cohort comprises 4662 persons with repeated measurements.
Pregnancy and alteration in smoking behavior are factors that influence body weight, whereas diabetic medication affects glucose levels. Therefore, participants of the Doetinchem cohort who changed their smoking habits (n ¼ 750), who had missing data on smoking status (n ¼ 11), who were pregnant at the time of measurement (n ¼ 122), or who took diabetic medication (n ¼ 76) were excluded from this study. The second and third measurement rounds included glucose measurements and were used for this study. However, glucose levels were not measured in the beginning of round 2 from January to April 1993, and thus another 255 subjects were excluded. This resulted in a final study population of 3448 participants.
General questionnaire and anthropometric measurements
During each measurement round, anthropometric data and data on lifestyle factors were collected. Data on pregnancy, smoking status (none, ex-, current smoker), and physical activity were obtained by a standardized questionnaire. 10 The Cambridge Physical Activity Index, as described by Wareham et Selection of candidate genes and SNPs A total of 253 candidate genes were selected by a pathwaydriven approach, with emphasis on regulatory pathways that control fatty acid, glucose, cholesterol, and bile salt homeostasis. 10, 13 In short, the selection procedure started from the master regulator genes encoding nuclear receptors (PPARs, LXR, NR1H4) and transcription factors (SREBPs) and continued by selecting their co-activators, co-repressors, and target genes. In addition, hormonal receptors (insulin receptor) and their down-stream signaling proteins were selected. For each gene out of these pathways, one to seven SNPs were selected using the procedure described in detail elsewhere. 10 Finally, a set of 383 SNPs across 253 candidate genes passed the Illumina Assay Design Tool and were included.
Genotyping
Genomic DNA was extracted from the buffy coat fraction with a salting out method. 14 A total of 139 subjects were not eligible for genotyping, mainly because of failure to extract DNA or unavailability of buffy coats. For 3309 subjects, high-throughput SNP genotyping was performed with the Illumina Golden Gate assay using the Sentrix Array Matrix platform (Illumina Inc., San Diego, CA, USA); 15 Sixty-five subjects were excluded because of genotype failure or discordance on gender control and 28 SNPs were excluded because genotyping was unsuccessful. In addition, 33 SNPs were not in Hardy-Weinberg Equilibrium (HWE). Verification was carried out in a random sample (n ¼ 96) for the eight SNPs (24%) that deviated most strongly from HWE. All yielded the same results, except for two SNPs, which were, therefore, excluded. 16 Thus, data on 353 SNPs in 239 genes were available for 3244 participants.
Study on lifestyle intervention and impaired glucose tolerance Maastricht All SNPs, which were measured in the Doetinchem study were also measured in the study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM), using the same Illumina array. Study design, inclusion, and exclusion criteria of SLIM, an intervention study, have earlier been described in detail. 17 In short, BMI and fasting plasma were not used, because in these years, information was only available for 68 participants.
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Statistical analyses
All analyses were performed with SAS version 9.1 (SAS Institute, INC., Cary, NC, USA). Distributions of genotypes were tested for deviation from HWE by C 2 analyses (PROC ALLELE). As the glucose distribution was skewed, glucose values were log-transformed. Repeated measurements of logglucose and BMI were used in multilevel random coefficient models (PROC MIXED) to study interaction effects of SNPs Â BMI on log-glucose levels. This model accounts for correlation between repeated measures within subjects. To account for individual differences in glucose levels, a random intercept was used. Analyses were adjusted for age, sex, time since last meal (continuous), time since last meal (p2 h; 42 h), and follow-up time. After a meal, glucose levels peak shortly, and they return to near normal levels in approximately 2 h. After 2 h glucose levels decrease slowly. 18 The false discovery rate (FDR), which is a commonly accepted method in high-throughput genomic studies, was used to adjust for multiple testing. 19, 20 Significance was defined as FDRp0.20. 21 When a significant interaction was found, the association between the SNP and log-glucose, stratified by BMI (p25, 425 kg m -2 and p28, 428 kg m -2 )
was analyzed. The cut-off points of 25 and 28 kg m -2 equal, respectively, the 50th and 75th percentile of the study population rounded to the nearest whole number. The model used was similar to that of the interaction analyses.
For the stratified and replication analyses, significance was defined as a P-value p0.05.
Results
Doetinchem cohort
Among the 3244 subjects of the Doetinchem cohort, median non-fasting glucose levels increased from 5.1 mmol l -1 (P25-P75: 4.7-5.6) in round 2 to 5.2 mmol l -1 (P25-P75: 4.8-5.8) in round 3 ( Table 1 ). The number of participants with elevated non-fasting glucose levels (X11.1 mmol l -1 ) was small, n ¼ 2 and n ¼ 17 in round 2 and round 3, respectively. BMI also increased slightly from round 2 to round 3. The overall correlation coefficient between log-glucose and BMI was 0.22 (Po0.001).
Two out of the 353 SNPs, rs8192678 (P-value ¼ 0.0002; FDR ¼ 0.07) and rs3755863 (P ¼ 0.0012; FDR ¼ 0.17), showed a significant interaction with BMI after adjustment for multiple testing. The results were similar after additional adjustment for physical activity in a subgroup of 2844 people with data available (rs8192678*BMI-Po0.0001; rs3755863* BMI-P ¼ 0.0005). The rs8192678 and rs3755863 SNP of the PPARGC1A gene, better known as Gly482Ser and Thr528Thr, were highly correlated (r 2 ¼ 0.88; Po0.001). Both SNPs were in HWE (rs8192678, P ¼ 0.14; rs3755863, P ¼ 0.25).
In subjects with a BMIp25 kg m -2 , the A/A genotype of rs8192678 (P ¼ 0.02) and rs3755863 (P ¼ 0.03) was significantly associated with lower log-glucose levels ( Table 2 ). In contrast, in subjects with a BMI428 kg m -2 , an opposite trend was found and the A/A genotype of both SNPs was associated with slightly higher log-glucose values (rs8192678, P ¼ 0.12; rs3755863, P ¼ 0.14). No association was found in subjects with a BMI between 25 
Discussion
In this explorative study of 353 SNPs, mainly located in pathways related to lipid and glucose metabolism, we found a significant interaction between two SNPs in the PPARGC1A gene (rs8192678; rs3755863) and BMI on glucose levels. The rare allele of both SNPs was associated with lower glucose levels in subjects with a BMIp25 kg m -2 , but with higher glucose levels in subjects with a BMI428 kg m -2
. A small cohort study of 120 mainly overweight or obese subjects suggested a similar association.
PPARGC1A is a transcriptional co-activator that interacts with a broad range of transcription factors involved in a wide variety of biological processes, including glucose metabolism in the liver and muscle, mitochondrial biogenesis, lipid oxidation, and adipocyte differentiation. 22 One of the transcription factors regulated by PPARGC1A is PPARG. In line with the interaction effect of PPARGC1A with BMI in our study, Wei et al. 7 found a significant interaction effect between two SNPs in the PPARG gene (rs4135304; rs4135247) and BMI on fasting plasma glucose levels in African Americans. For both polymorphisms, allelic effects on glucose levels were reversed among individuals with lower BMI and individuals with higher BMI. However, neither Wei et al. 7 nor we observed an interaction effect between BMI and the well-studied rs1801282 (Pro12Ala) polymorphism of PPARG. Interestingly, we found an interaction effect with another SNP in the PPARG gene, the rs3856806 polymorphism (P ¼ 0.04). However, this interaction was no longer statistically significant after adjustment for multiple testing. Besides, we found interactions with BMI for SNPs in other genes of the PPARGC1A pathway (GSK3B, UCP2, PCK2, EP300, LIPC, PPARG, and AKT2) under a significance level of Po0.05. These associations were no longer statically significant after adjustment for multiple testing. Furthermore, to the best of our knowledge, there are no other human studies showing an interaction between BMI and SNPs in these genes on glucose levels.
Owing to the high correlation between rs8192678 and rs3755863, both SNPs showed similar associations with serum glucose levels. Of these SNPs, rs8192678 or Gly482Ser induces a change in the amino-acid sequence, whereas rs3755863 or Thr528Thr does not. Although the amino-acid change induced by the Gly482Ser polymorphism has not been shown to affect a regulatory region within PPARGC1A, 23 Ling et al. 24, 25 showed that the Gly482Ser polymorphism changed PPARGC1A mRNA expression. In short, the Gly482Ser is more likely to be a functional polymorphism than Thr528Thr polymorphism. The Ser allele of the Gly482Ser mutation has been related to diabetes 26 and obesity. 27, 28 In a meta-analysis of eight studies, the Ser allele of the Gly482Ser polymorphism was associated with modest increase of type 2 diabetes risk. 26 However, in the same meta-analysis, no association was found with fasting glucose levels or fasting insulin levels. This may be due to between-study heterogeneity, which could result from differences in genetic or environmental factors. Indeed, several environmental factors, such as age, 25, 28, 29 physical activity, 28, 30 and acarbose treatment, 31 have been shown to interact with the Gly482Ser polymorphism. Furthermore, Goyenechea et al. 32 showed in an 8-week weight loss trial that insulin resistance decreased significantly more in Ser/Ser subjects compared with Gly/Ser and Gly/Gly subjects, whereas the decrease in body weight and adiposity were similar among the different genotypes. These results support our finding that body weight modifies the association between the Gly482Ser polymorphism and glucose. The Ser allele of the Gly482Ser polymorphism has been shown to correlate with decreased PPARGC1A mRNA expression in muscle 25 and insulin islets. 24 We speculate that the Ser allele may also down-regulate PPARGC1A expression in other tissues. Down-regulation of PPARGC1A in liver and muscle has opposite effects on glucose levels. In liver, PPARGC1A down-regulation decreases gluconeogenesis, 22 which has a blood glucose lowering effect. In contrast, in vitro studies suggest that down-regulation of PPARGC1A in muscle increases insulin resistance by down-regulating GLUT4 transporters 22 and by stimulating muscle lipid accumulation. 33 This, in turn, increases blood glucose levels.
Our results suggest that body weight affects the balance between the glucose lowering and glucose increasing processes. We hypothesize that in lean people, the Ser allele may decrease glucose levels through decreased gluconeogenesis, whereas in obese people, who are generally more insulin resistant, the balance may shift toward increased insulin resistance properties of the Ser allele, leading to increased glucose levels. Strengths of this pathway-driven candidate gene study were the relatively large sample size and the availability of repeated anthropometric measurements, which improve study power and precision. Furthermore, the SLIM study showed a similar interaction with a larger effect size. Owing to the smaller sample seize, these results were, however, not SNP Â BMI interaction effects on glucose levels CM Povel et al statically significant. Our blood samples were taken from non-fasting subjects. To account for this, we corrected our analysis for the time since the last meal. Moreover, the error induced by the non-fasting state of the subjects is of random rather than of systematic nature. As mention above, our findings are in line with evidence from other studies and might be biologically plausible. Nevertheless, it cannot be excluded that our results are based on chance alone.
In this explorative study among 3244 subjects investigating 353 SNPs in 253 candidate genes, we emphasized on the intricate links between glucose and lipid metabolism through common transcriptional factors. We found that BMI significantly modifies the association between two SNPs in the PPARGC1A gene (rs8192678; rs3755863) and glucose levels. Although the Ser/Ser genotype of PPARGC1A was associated with lower glucose levels in leans subjects, it may be inversely associated in obese people. This suggests that the effect of the polymorphisms in the PPARGC1A gene, which is involved both in fatty acid and glucose metabolism, is modified by BMI. On the basis of this study, it can be speculated that Ser/Ser subjects are more susceptible to the development of hyperglycemia in an obesogenic environment, but less susceptible to develop hyperglycemia in a non-obesogenic environment.
